Oxford Pharmascience Group plc has signed a license agreement with Bayer Consumer Care AG (BYR.L,BAYRY.PK,BAYZF.PK) in Basel to allow them to manufacture a calcium and Vitamin D soft chew using the Company's OXP chew technology. Pursuant to the deal, Bayer is being awarded a ten year license to manufacture a calcium and vitamin D soft chew product.
Nigel Theobald, Chief Executive, Oxford Pharmascience Group Plc, commented: "Partnering with Bayer is further evidence of our credibility in commercialising our technology platforms with major pharmaceutical companies. This is our first commercial relationship with a major global pharmaceutical company and their commitment and interest in our technologies is further evidence that our new strategic direction is working."
Click here to receive FREE breaking news email alerts for Bayer AG and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org